CLINICAL TRIALS PROFILE FOR ZIRGAN

All Clinical Trials for ZIRGAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01533480 ↗	A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis	Completed	Bausch & Lomb Incorporated	Phase 4	2012-01-01	The investigators are conducting this study because the patient have an eye infection which is called adenoviral conjunctivitis, and is the most common cause of "pink eye". There is currently no treatment for this condition. However, the researchers associated with this study want to understand if using a product called Zirgan, which is a topical ointment that is already FDA-approved for other types of eye infections, will help with the type of infection that the patient currently have. Zirgan is not FDA-approved to treat your type of eye infection. Your participation in this study is expected to last 21 days but the patient will only apply the topical ointment for 14 of those days. During the study, the patient will be asked to come into this clinic 8 times. The purpose of this study is to determine whether topical Zirgan can reduce days that the patient suffers from the eye infection, and also to see if it can prevent the infection from spreading to your second eye and to also see if it can prevent the spreading of the infection to people that the patient come in close contact with. Zirgan will be compared to Genteal Gel in this trial. Genteal Gel is a non-prescription eye lubricant gel and is commonly used for treatment of dry eye. The patient will be asked to apply a topical ointment (either Zirgan or Genteal gel 5 times a day for the first 7 days and then 3 times a day for the following 7 days. The patient will be asked to return to the clinic 21 days after the patient starts the study for a final check-up. It is planned that about 80 people with Adenovirus Conjunctivitis will be enrolled in this study between 8-12 sites across the United States. The patient will be assigned to either Zirgan or Genteal gel by chance which is similar to flipping a coin. The study groups will be assigned in a 1:1 ratio. Neither the patient nor the study doctor or study staff will be able to pick which study group The patient is in. The patient will not know and the study doctor or study staff will not know which study group the patient is in. The study doctor or study staff can find out if it is necessary to know for your health. If this happens, the study doctor or study staff may not be able to tell the patient which study group the patient was in until everyone finishes the study.
NCT01533480 ↗	A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis	Completed	Lifelong Vision Foundation	Phase 4	2012-01-01	The investigators are conducting this study because the patient have an eye infection which is called adenoviral conjunctivitis, and is the most common cause of "pink eye". There is currently no treatment for this condition. However, the researchers associated with this study want to understand if using a product called Zirgan, which is a topical ointment that is already FDA-approved for other types of eye infections, will help with the type of infection that the patient currently have. Zirgan is not FDA-approved to treat your type of eye infection. Your participation in this study is expected to last 21 days but the patient will only apply the topical ointment for 14 of those days. During the study, the patient will be asked to come into this clinic 8 times. The purpose of this study is to determine whether topical Zirgan can reduce days that the patient suffers from the eye infection, and also to see if it can prevent the infection from spreading to your second eye and to also see if it can prevent the spreading of the infection to people that the patient come in close contact with. Zirgan will be compared to Genteal Gel in this trial. Genteal Gel is a non-prescription eye lubricant gel and is commonly used for treatment of dry eye. The patient will be asked to apply a topical ointment (either Zirgan or Genteal gel 5 times a day for the first 7 days and then 3 times a day for the following 7 days. The patient will be asked to return to the clinic 21 days after the patient starts the study for a final check-up. It is planned that about 80 people with Adenovirus Conjunctivitis will be enrolled in this study between 8-12 sites across the United States. The patient will be assigned to either Zirgan or Genteal gel by chance which is similar to flipping a coin. The study groups will be assigned in a 1:1 ratio. Neither the patient nor the study doctor or study staff will be able to pick which study group The patient is in. The patient will not know and the study doctor or study staff will not know which study group the patient is in. The study doctor or study staff can find out if it is necessary to know for your health. If this happens, the study doctor or study staff may not be able to tell the patient which study group the patient was in until everyone finishes the study.
NCT02382588 ↗	Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis	Terminated	Bausch & Lomb Incorporated	Phase 2	2013-12-10	The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis. Half the patients will receive the study drug while the other half of the patients will receive the placebo
NCT02382588 ↗	Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis	Terminated	Northwestern University	Phase 2	2013-12-10	The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis. Half the patients will receive the study drug while the other half of the patients will receive the placebo

Clinical Trial Conditions for ZIRGAN

Condition Name

Condition Name for ZIRGAN
Intervention	Trials
Herpes Zoster Keratitis	1
Keratoconjunctivitis Due to Adenovirus	1
Viral Shedding	1

Condition MeSH

Condition MeSH for ZIRGAN
Intervention	Trials
Herpes Zoster Ophthalmicus	1
Herpes Zoster	1
Keratoconjunctivitis	1
Conjunctivitis	1

Clinical Trial Locations for ZIRGAN

Trials by Country

Trials by Country for ZIRGAN
Location	Trials
United States	2

Trials by US State

Trials by US State for ZIRGAN
Location	Trials
Illinois	1
Missouri	1

Clinical Trial Progress for ZIRGAN

Clinical Trial Phase

Clinical Trial Phase for ZIRGAN
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for ZIRGAN
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for ZIRGAN

Sponsor Name

Sponsor Name for ZIRGAN
Sponsor	Trials
Bausch & Lomb Incorporated	2
Lifelong Vision Foundation	1
Northwestern University	1

Sponsor Type

Sponsor Type for ZIRGAN
Sponsor	Trials
Industry	2
Other	2

ZIRGAN Market Analysis and Financial Projection

Last updated: May 4, 2026

ZIRGAN (ganciclovir ophthalmic gel): Clinical-trial status, market analysis, and supply-side projection

What is ZIRGAN and what is its regulatory positioning?

ZIRGAN is an ophthalmic formulation of ganciclovir in gel form, approved for viral infections of the eye. The product name and commercial launch pattern vary by territory because ganciclovir ophthalmics have long been administered across multiple jurisdictions under different brands and channel structures, with ZIRGAN used as the brand for a specific gel product line in certain markets.

Core commercial implication: ZIRGAN is a mature, product-life-cycle drug with limited scope for incremental clinical differentiation versus older ganciclovir ophthalmic regimens. Market performance is driven mainly by (i) usage frequency in ophthalmic viral indications, (ii) payer formulary position, (iii) channel availability (retail vs hospital/clinic pull-through), and (iv) competition from branded and generic antivirals.

---

What clinical-trials signal matters for ZIRGAN now?

No current, decision-grade late-stage trial readouts were identified in the available basis for this response. For a mature ophthalmic antiviral like ZIRGAN, business-relevant clinical updates typically come from:

• label expansion (new viral species, new age group, new disease stage),
• comparative trials against other antivirals (e.g., other nucleoside analogs or adjuvant regimens),
• pharmacokinetic/pharmacodynamic bridging for formulation changes.

For investment and R&D planning, the key point is that a mature ophthalmic gel brand generally has low probability of near-term label growth absent a new formulation or novel delivery.

Clinical-trial status used for market projection below: treat ZIRGAN as commercially active without incremental late-stage catalysts identified in the provided basis.

---

How big is the ZIRGAN market and what drives demand?

Demand drivers

ZIRGAN demand correlates with:

1. Incidence of herpes simplex keratitis (HSK) and other viral keratitis presentations that map to ganciclovir gel use patterns.
2. Seasonality and outbreak dynamics (minor effect versus baseline disease incidence).
3. Physician prescribing behavior and local guideline adherence in ophthalmology.
4. Cost-sharing and formulary tier for antiviral ophthalmics.

Market mechanism: ophthalmology procurement

Ophthalmic antivirals are typically bought through:

• retail pharmacy for outpatient management,
• clinic-based dispensing in some systems,
• hospital pharmacy pull-through when initial presentation occurs via ER/urgent ophthalmic pathways.

Implication: ZIRGAN revenue tends to be volume-driven, not price-extraction-driven, once generics and therapeutic alternatives exist.

---

Who are the competitive substitutes and how do they pressure pricing?

Competitive pressure for ganciclovir ophthalmics typically comes from:

• alternative topical antivirals used for HSV keratitis and related viral conjunctival or keratitis syndromes,
• generic versions of older ophthalmic antivirals (where approvals and sourcing permit),
• off-label prescribing based on clinician preference and historical outcomes.

Even when ZIRGAN maintains brand preference, pricing pressure is common because ophthalmology antiviral products face:

• payer drive to generic substitution for “same active, same indication” constructs,
• switching behavior when clinical practice has acceptable outcomes across multiple agents.

---

What is the commercialization trajectory implied by ZIRGAN’s maturity?

With no identified near-term late-stage clinical catalyst and given the typical lifecycle pattern of ophthalmic antivirals, the most defensible trajectory model is:

• base revenue retention from ongoing treated incidence,
• margin compression if generic or alternative products gain formulary position,
• stable-to-slow growth driven by population and diagnosis trends.

Operationally, ZIRGAN’s projection depends more on access and continuity of supply than on new clinical evidence.

---

Market projection: revenue, units, and scenario structure

Because a complete numeric forecast requires territory-specific data (incidence, penetration, payer mix, channel mix, and competitor pricing), and none is provided in the basis for this response, the only allowable projection here is a framework with explicit business levers rather than unsupported dollar/unit totals.

Scenario framework (2026–2030)

Base case (no label expansion):

• Volume: flat to low growth tied to treated incidence.
• Price: mild declines from formulary and competitive pressure.
• Net revenue: low single-digit CAGR.

Downside (accelerating generic substitution or formulary downgrades):

• Volume: modest contraction from substitution.
• Price: faster declines due to reference pricing and payer actions.
• Net revenue: negative CAGR.

Upside (renewed guideline emphasis, improved access, or formulation channel wins):

• Volume: low growth uplift from improved adherence and access.
• Price: stable if brand remains preferred on key formularies.
• Net revenue: mid single-digit CAGR.

Business levers that move the needle

• Formulary positioning in top dispensing geographies.
• Reimbursement status (preferred vs non-preferred tiers).
• Channel execution for ophthalmic clinics and urgent care networks.
• Supply continuity (avoid stock-outs that reduce physician confidence).
• Guideline alignment and educational pull-through for ophthalmology practices.

---

Supply-side projection: what matters for continuity

For mature ophthalmic products, the highest operational risk typically comes from:

• manufacturing scale consistency for sterile ophthalmic gel production,
• regulatory batch release timelines,
• component supply fragility,
• distributor concentration and fill-rate performance.

In a clinical-catalyst-light environment, market outcomes often track supply and access. If supply remains stable, ZIRGAN performance tends to mirror demand incidence and access. If supply degrades, lost demand is hard to recover.

---

Key takeaways

• ZIRGAN is a mature ganciclovir ophthalmic gel whose business performance depends primarily on treated incidence, access, reimbursement, and channel execution rather than incremental clinical catalysts.
• No decision-grade late-stage clinical update basis is available here; treat ZIRGAN as commercially steady without near-term label expansion catalysts.
• Competitive pressure is structurally present via alternative antivirals and generic substitution pathways, which typically drive price erosion and penetration shifts.
• A credible 2026–2030 outlook is low single-digit base-case growth, with downside tied to formulary downgrades and upside tied to access improvements and guideline alignment, not new science.

---

FAQs

1) Is ZIRGAN expected to have major label expansion soon?

Business-grade labeling growth is unlikely in the absence of an identified late-stage program or formulation change catalyst; base-case planning should assume status quo indication scope.

2) What is the main driver of ZIRGAN revenue changes?

Access and reimbursement (formulary tier, preferred status, and channel pull-through) drive the majority of revenue variance more than clinical demand fluctuations.

3) How does competition usually impact ZIRGAN pricing?

Competitors and generic substitution typically cause gradual price compression as payers implement reference pricing and tiering.

4) What operational factor most affects ophthalmic antiviral sales?

Supply continuity and fill-rate reliability; disruptions reduce prescribing confidence and can cause sustained lost demand.

5) What is the most practical way to model ZIRGAN future performance?

Model incidence-driven volume plus penetration shifts driven by formulary access, then apply scenario-based price curves based on competitive intensity.

---

Sources

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] European Medicines Agency (EMA). Medicines database. https://www.ema.europa.eu/